TRT and Lipids Evidence on Cholesterol and Triglycerides

Estimated reading time: 9 minutes

Key takeaways

In the first 6–12 months, TRT modestly lowers total cholesterol and triglycerides; LDL-C and HDL-C often remain unchanged.
Longer-term observational data suggest broader lipid improvements (lower TC, LDL-C, TG, non-HDL, remnant cholesterol; higher HDL), but causality is unproven.
Early, small HDL decreases can occur and may reverse over time; clinical significance is uncertain.
As of Feb 28, 2025, the FDA removed the boxed cardiovascular risk warning and added class-wide blood pressure warnings; monitor BP routinely.
Check fasting lipids at baseline and 6–12 months, then periodically; integrate TRT within comprehensive cardiometabolic risk management.

Why lipids matter in hypogonadal men
What the clinical evidence shows about TRT and the lipid profile
How TRT might influence cholesterol and triglycerides
Safety, monitoring, and the 2025 FDA updates
Practical implications for cardiologists and internists
Who may benefit most from lipid improvements with TRT?
What we still don’t know
Putting it together: a clinician’s checklist
Conclusion

Why lipids matter in hypogonadal men

Men with low testosterone often present with central adiposity, insulin resistance, and atherogenic dyslipidemia—elevated triglycerides, low HDL-C, and sometimes higher LDL-C or non-HDL cholesterol. Improving this lipid profile can reduce residual cardiovascular risk in men already managed for hypertension, diabetes, or obesity. For clinicians weighing TRT in symptomatic men with confirmed testosterone deficiency, understanding its effect on the lipid profile is an important part of shared decision-making.

What the clinical evidence shows about TRT and the lipid profile

Short-term outcomes (6–12 months): A clinical study in hypogonadal men showed significant reductions in total cholesterol (from 183.7 to 175.5 mg/dL at 6 months; p=0.001) and triglycerides (from 147.2 to 131.2 mg/dL; p=0.009), with no significant changes in LDL-C or HDL-C (PubMed).
Long-term observational outcomes (up to 12 years): In an office-based injection registry of overweight/obese men with functional hypogonadism, sustained reductions were observed versus controls in total cholesterol, LDL-C, triglycerides, non-HDL cholesterol, and remnant cholesterol, with increases in HDL-C (all p<0.0001). Adherence was enforced through in-office injections, supporting durability—but data are observational and susceptible to bias (Endocrine Abstracts).
TRT in men with type 2 diabetes: A meta-analysis of hypogonadal men with T2DM reported reductions in total cholesterol (−6.44 mg/dL) and triglycerides (−27.94 mg/dL), with inconsistent LDL-C effects across studies (Systematic review and meta-analysis).

In aggregate, the pattern is consistent: modest short-term drops in total cholesterol and triglycerides, followed by potential longer-term improvements across the broader lipid panel in adherent patients. However, the magnitude and consistency of LDL-C and HDL-C changes vary by study design, population, TRT formulation, adherence, and concurrent lifestyle or pharmacologic interventions.

How TRT might influence cholesterol and triglycerides

Body composition and insulin sensitivity: Physiologic testosterone restoration may reduce visceral adiposity and improve insulin sensitivity, secondarily improving triglyceride-rich lipoprotein metabolism. This aligns with larger TG reductions in men with T2DM and obesity.
Enzymatic activity in lipid metabolism: Testosterone may influence hepatic lipase and lipoprotein lipase activity, affecting HDL remodeling and triglyceride clearance. Early HDL dips may reflect complex remodeling, but clinical implications remain unsettled.
Inflammation: Consistent reductions in CRP or other inflammatory markers have not been confirmed by randomized data in the cited evidence; further trials are needed.

These mechanisms remain hypotheses; causality and clinical significance require more rigorous, long-term randomized trials.

Safety, monitoring, and the 2025 FDA updates

On February 28, 2025, the FDA issued class-wide labeling updates for testosterone products. Two points matter for lipid and cardiovascular decision-making:

The prior boxed warning suggesting increased cardiovascular risk was removed, informed in part by contemporary cardiovascular safety data in appropriately indicated men.
New warnings highlight class-wide blood pressure increases measured by ambulatory blood pressure monitoring (ABPM), reinforcing the need for baseline and follow-up BP measurement.

See the FDA communication for details: FDA class-wide labeling changes.

Standard monitoring for men on TRT typically includes hematocrit (for erythrocytosis risk), PSA and prostate evaluation per age and risk, and assessment of adherence and adverse effects. From a dyslipidemia perspective, it is reasonable to check fasting lipids at baseline, around 6–12 months, and then periodically thereafter—particularly in men with coexisting T2DM, obesity, or metabolic syndrome. Importantly, TRT is intended for men with confirmed biochemical hypogonadism and compatible symptoms—not for age-related nonspecific fatigue.

Practical implications for cardiologists and internists

Expect TG and TC improvements first: In the first 6–12 months of TRT, modest reductions in total cholesterol and triglycerides are most consistent; LDL-C and HDL-C may be unchanged early.
HDL may dip early, then recover: Short-term HDL reductions are reported in some cohorts; longer-term data suggest HDL can increase with sustained therapy and adherence.
Consider the whole cardiometabolic picture: Integrate lipid changes with weight, waist circumference, glycemic control, blood pressure, smoking status, and ASCVD risk; continue indicated lipid-lowering therapies.
Monitor blood pressure: Incorporate routine BP checks into follow-up plans in light of ABPM data and labeling changes (FDA update).
Adherence matters: The most impressive long-term lipid improvements occurred in a program with near-100% adherence via in-clinic injections; real-world self-administered regimens may yield smaller or more variable effects.
Combine with lifestyle and weight loss: Diet, physical activity, and weight loss remain first-line; pairing guideline-directed cardiometabolic therapy with indicated TRT may be complementary.
Coordinate care: Align primary care, endocrinology, cardiology, and pharmacy follow-up to support adherence and timely labs.

Who may benefit most from lipid improvements with TRT?

The greatest lipid shifts are seen in hypogonadal men who also have features of metabolic disease—overweight/obesity and type 2 diabetes. In these groups, triglyceride reductions can be clinically meaningful, and non-HDL or remnant cholesterol improvements may add incremental risk reduction. Randomized trials have not yet confirmed translation to fewer cardiovascular events. Men without confirmed hypogonadism or those seeking TRT solely for age-related symptoms are unlikely to see favorable risk–benefit ratios.

What we still don’t know

Whether TRT reduces cardiovascular events via lipid changes; event-driven, long-term randomized trials are needed.
The significance of early HDL reductions—harmful, neutral, or part of remodeling.
Whether TRT reliably reduces CRP or other inflammatory markers and the clinical impact of such changes.
How TRT compares head-to-head with modern cardiometabolic agents. The SEMAT trial will test TRT versus semaglutide over 24 weeks in obese hypogonadal men with T2DM, with lipid outcomes among endpoints (ClinicalTrials.gov: NCT06489457).

Putting it together: a clinician’s checklist

Confirm diagnosis: Persistent low morning testosterone on appropriate assays plus compatible symptoms; assess reversible causes (reference study).
Baseline risk: Fasting lipids, BP, A1C/glucose, hematocrit, PSA/prostate risk assessment, and ASCVD risk estimation.
Shared goals: Align expectations—symptom relief plus potential lipid improvements—without assuming cardiovascular risk reduction.
Monitor and adjust: Lipids at 6–12 months, then periodically; reinforce adherence; manage BP per FDA guidance; continue evidence-based lipid-lowering therapy when indicated (FDA guidance).
Integrate lifestyle and weight loss: Maintain first-line interventions; consider combination strategies in T2DM/obesity.
Reassess benefit–risk over time: Discontinue or modify if risks outweigh benefits or if goals are not met.

Conclusion

For men with confirmed hypogonadism, TRT can produce meaningful improvements in the lipid profile—most notably early reductions in total cholesterol and triglycerides, with the possibility of broader, longer-term improvements when adherence is high. HDL changes are inconsistent, inflammation signals are unproven, and no definitive evidence shows that TRT reduces cardiovascular events via lipid changes. The 2025 FDA updates removed the prior boxed cardiovascular warning and highlighted blood pressure increases, reinforcing the need for careful monitoring. Bottom line: consider TRT’s lipid effects as one component of a comprehensive cardiometabolic plan, especially in hypogonadal men with obesity and type 2 diabetes, while awaiting further randomized data.

Disclaimer

This article is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Decisions about testosterone therapy should be made with a qualified clinician based on individual evaluation, lab results, and current guidelines.

TRT and Lipids Evidence on Cholesterol and Triglycerides